US 11352360
TGF-beta inhibitors
granted A61PA61P1/04A61P1/16
Quick answer
US patent 11352360 (TGF-beta inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61P, A61P1/04, A61P1/16, A61P11/00, A61P13/08